Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node...

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• The programmed death-1 (PD-1) pathway is crucial for T-cell regulation and antitumor immunity.
• Monoclonal antibodies targeting PD-1/PD-L1 show promise in various cancers, with PD-L1 expression potentially predicting response.
• Understanding PD-L1 expression in muscle-invasive bladder cancer (MIBC) is key for selecting patients for PD-1 therapy.

Purpose of the Study:

• To determine the frequency of PD-L1 expression in MIBC and associated lymph node metastases.
• To evaluate PD-L1 as a biomarker for patient selection in PD-1-directed therapy.

Main Methods:

• Retrospective analysis of 52 radical cystectomy specimens from patients without prior chemotherapy.
• Immunohistochemistry using an anti-PD-L1 antibody (5H1 clone).
• PD-L1 positivity defined as ≥5% expression in tumor cells or immune cells.

Main Results:

• PD-L1 overexpression was observed in tumor cells of 9.6% (5/52) and immune cells of 32.7% (17/52) of MIBC specimens.
• Significant discordance in PD-L1 expression was noted between primary tumors and lymph node metastases.
• This highlights potential challenges in using archived tissue for biomarker assessment.

Conclusions:

• Standardized assays for PD-L1 expression are still needed.
• Discordance between primary and metastatic sites suggests that pre-treatment biopsies are essential for accurate biomarker assessment.
• Future studies should prioritize fresh tissue acquisition immediately before therapy initiation.